Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

NCT06962449 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Cancer
Non-Small-Cell Lung Cancer Stage IV

Sponsor

Shanghai Chest Hospital